References
NSCLC, tumor
NON-SMALL CELL LUNG CANCER, TUMOR, NSCLC, MUTATION
Intention-to-treat (ITT) population and biomarker-evaluable population (BEP). NSCLC, non-small cell lung cancer; SEP, safety-evaluable population; cfDNA, circulating cell-free DNA; QC, quality control; NGS, next-generation sequencing; ctDNA, circulating tumor DNA; TMB, tumor mutation burden; VAF, variant allele frequency; SD, standard deviation.Atezolizumab efficacy according to the bTMB in the ctDNA BEP (Atezolizumab efficacy according to the cfDNA concentration in the cfDNA BEP (Atezolizumab efficacy according to the hVAF in the ctDNA BEP (Atezolizumab efficacy according to the VAFSD in the ctDNA BEP (Mutation profiling according to the clinical benefit rate (CBR). (Baseline characteristics of the enrolled patients.Values are presented as the median (range) or number (%). Efficacy of the atezolizumb treatment in the ITT population.Values are presented as the median (range) or number. 